Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

6.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K
Metastasis02:30

Metastasis

3.8K
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier, and distribution to tumor cells in HER2+ brain metastasis model systems.

Neuro-oncology·2026
Same author

Proteogenomic characterization of invasive breast tumors in young women.

NPJ breast cancer·2025
Same author

Navigating the oncology drug discovery and development process with programmes supported by the National Institutes of Health.

The Lancet. Oncology·2024
Same author

Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer.

Neuro-oncology·2024
Same author

The murine metastatic microenvironment of experimental brain metastases of breast cancer differs by host age in vivo: a proteomic study.

Clinical & experimental metastasis·2023
Same author

A perspective on the metastasis suppressor field.

Cancer metastasis reviews·2023

Related Experiment Video

Updated: Mar 23, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Targeting metastasis.

Patricia S Steeg1

  • 1Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

Nature Reviews. Cancer
|March 25, 2016
PubMed
Summary
This summary is machine-generated.

Targeting interactions between tumour cells and their microenvironment can prevent cancer metastasis, a major cause of cancer deaths. This review re-examines preclinical research and clinical trials to improve patient outcomes.

More Related Videos

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
05:23

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

1.7K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

17.7K

Related Experiment Videos

Last Updated: Mar 23, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K
Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread
05:23

Author Spotlight: Decoding Metastasis-to-Metastasis Seeding Using a New In Vivo Technique for Tracking Breast Cancer Spread

Published on: July 7, 2023

1.7K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

17.7K

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • Tumour metastasis, the spread of cancer cells to distant organs, is a primary cause of cancer-related mortality.
  • Therapeutic strategies aim to prevent initial metastasis, shrink existing tumours, and halt further spread.
  • Tumour cells dynamically interact with their microenvironment, influencing immunity, genomic stability, and treatment resistance.

Purpose of the Study:

  • To re-examine preclinical research, combination therapies, and clinical trial designs focused on targeting tumour-microenvironment interactions.
  • To evaluate the potential of targeting these interactions to improve patient outcomes in cancer metastasis.

Main Methods:

  • Review of existing preclinical research on tumour metastasis and microenvironment interactions.
  • Analysis of combination therapy strategies.
  • Examination of clinical trial designs for metastatic cancer.

Main Results:

  • Tumour cells are not autonomous and engage in critical bidirectional communication with their metastatic microenvironments.
  • These interactions modulate key cancer hallmarks including antitumour immunity, extracellular matrix, genomic stability, and therapeutic resistance.
  • The potential for targeting these complex interactions requires further investigation.

Conclusions:

  • Targeting the bidirectional interactions between tumour cells and their metastatic microenvironments holds significant promise for improving cancer patient outcomes.
  • A comprehensive re-evaluation of preclinical data and clinical trial strategies is necessary to fully exploit these interactions therapeutically.
  • Further research into combination therapies that disrupt tumour-microenvironment crosstalk is warranted.